Andre Goy, MD
Although it is a treatment goal for patients with mantle cell lymphoma (MCL) to achieve a minimal residual disease (MRD)-negative state and experience extended durations of response to therapy, most of them will relapse, according to Andre Goy, MD.
on Hematologic Malignancies, Goy, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discussed the evolution of MCL treatment, specifically the integration of new agents in both the frontline and relapsed/refractory settings, and the importance of MRD status and maintenance therapies.
OncLive: How has the field of MCL evolved?
: The field of MCL is rapidly evolving. We now have 5 newly approved novel therapies between the United States and Europe that have begun to be integrated into standard frontline regimens. We know that rituximab (Rituxan), cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP) alone or bendamustine and rituximab (BR) alone is not sufficient in MCL. The median progression-free survival (PFS) with R-CHOP is 14 to 18 months as patients become chemoresistant over time.
... to read the full story